Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: HRS7535, safiglipron
HRS-7535, also identified as safiglipron, is a synthetic small-molecule GLP-1 receptor agonist intended for oral administration. Human studies have evaluated it in healthy participants and in participants with type 2 diabetes, obesity, and diabetic kidney disease. Clinical evidence remains investigational; no catalog-appropriate common reference size was established from authoritative scientific sources.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
HRS-7535 is an investigational compound. Available authoritative evidence supports oral clinical administration and pharmacokinetic characterization, but does not establish a general-purpose laboratory storage condition, aqueous solubility profile, or standardized catalog reference size. Clinical study doses and regimens are recorded only as neutral research-reference information and are not prescribing or self-administration guidance.
Supplementary research context only. Not medical advice or a treatment recommendation.
PubChem CID 166094939; molecular formula C32H31ClFN3O5; InChIKey YPJSZRLSBAIGIE-PZGXJGMVSA-N; molecular description: 2-[[4-[(3S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperidin-1-yl]methyl]-1-[(2S)-2-oxetanylmethyl]-1H-benzimidazole-6-carboxylic acid.
In a phase 1 randomized trial in healthy participants, single oral doses of 15, 60, and 120 mg were studied, along with a 90 mg food-effect cohort. A multiple-ascending-dose cohort received daily oral dosing for 28 days using a 30/60/90/120 mg titration scheme. Median time to maximum concentration was 5.98–5.99 hours in the single-dose study and 5.98–10.98 hours after repeated dosing. In a phase 2 type 2 diabetes trial, once-daily oral doses of 15, 30, 60, and 90 mg were studied for 16 weeks; the 60 and 90 mg groups used dose-escalation regimens. A phase 2 obesity trial evaluated once-daily target doses of 30, 60, 120, and 180 mg. A phase 2 diabetic kidney disease trial evaluated once-daily 30 and 90 mg doses for 16 weeks.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention HRS-7535 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.